Welcome to LookChem.com Sign In|Join Free
  • or
N-(2,3-dihydro-1H-inden-5-yl)-4-(trifluoromethoxy)benzamide is a complex organic compound with the molecular formula C17H14F3NO3. It is a derivative of benzamide, featuring a trifluoromethoxy group at the 4-position and a 2,3-dihydro-1H-inden-5-yl group at the nitrogen atom. N-(2,3-dihydro-1H-inden-5-yl)-4-(trifluoromethoxy)benzamide is known for its potential applications in pharmaceutical research, particularly as a chemical intermediate or a precursor in the synthesis of various drugs. Its structure provides a unique set of properties that can be exploited in the development of new therapeutic agents, making it a subject of interest in medicinal chemistry.

5579-42-0

Post Buying Request

5579-42-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5579-42-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 5579-42-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,5,7 and 9 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 5579-42:
(6*5)+(5*5)+(4*7)+(3*9)+(2*4)+(1*2)=120
120 % 10 = 0
So 5579-42-0 is a valid CAS Registry Number.

5579-42-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name N-(2,3-dihydro-1H-inden-5-yl)-4-(trifluoromethoxy)benzamide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5579-42-0 SDS

5579-42-0Upstream product

5579-42-0Downstream Products

5579-42-0Relevant academic research and scientific papers

Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors

-

, (2008/06/13)

This invention provides compounds having the structure: wherein X=CH, C(CH3) or N; each of R1, R2, R3, R4 and R5 is independently H, C1-C10 straight chained or branched alkyl, C2-C10 straight chained or branched alkenyl, C2-C10 straight chained or branched alkynyl, C3-C10 cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, —CN, —C(═Z)R6, —C(═Z)OR6, —C(═Z)N(R6)2, —N(R6)—C(═Z)R6, —N(R6)—C(═Z)N(R6)2, —OC(═Z)R6, —C(═Z)OR6—OR6 or —SR6; wherein Z is O or S; and wherein R6 is C1-C10 straight chained or branched alkyl, aryl, (CH2)nQ, C2-C10 alkenyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, wherein Q is OR7, SR7, N(R7)2 or aryl, wherein R7 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, wherein R2 and R3 and the carbons to which they are attached form a fused aryl, heteroaryl, C5-C10 cyclic alkyl or heterocyclic alkyl ring; or wherein R3 and R4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring; and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from Ra, where Ra is 1) hydroxy, 2) C1-C10 alkoxy, 3) halogen, 4) nitro, 5) amino, 6) CF3, or 7) carboxy, and each cycloalkyl group is optionally substituted with a substituent independently selected from Rb, where Rb is 1) a group selected from Ra, 2) C1-C7 alkyl, 3) C2-C7 alkenyl, 4) C2-C7 alkynyl or 5) cyclic C1-C10 alkyl, and each aryl is optionally substituted with R1. This invention also provides methods of treating pain, urge incontinence; as well as methods of preparing the compounds.

Compounds for the treatment of pain

-

, (2008/06/13)

This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 5579-42-0